News Opinion Fellow Talk My Picks for Fellows Attending TCT 2017 Amit K. Gupta, MBBS, MD October 26, 2017
News Conference News TCT 2017 TCT 2017: High Hopes in Denver for Complex PCI, Shorter DAPT Durations, TAVR Costs, and More Shelley Wood October 20, 2017
News Daily News Absorb BVS Again Linked to Scaffold Thrombosis at 1 Year and Beyond Michael O'Riordan October 17, 2017
News Daily News Bioresorbable Scaffolds Not to Be Chosen Over DES, Says European Task Force Michael O'Riordan October 11, 2017
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for September 2017 Shelley Wood September 30, 2017
News Features Absorb Vanishes, but Can Other Bioresorbable Scaffolds Make Magic Happen? Michael O'Riordan September 13, 2017
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for August 2017 Caitlin E. Cox August 31, 2017
News Daily News Boston Scientific Scraps Biodegradable Scaffold Program Michael O'Riordan August 01, 2017
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for July 2017 Shelley Wood July 31, 2017
News Daily News New Absorb BVS Meta-analysis Begs the Question: When to Stop Studying a First-Gen Device? Shelley Wood July 21, 2017
News Daily News ABSORB II Substudy Digs Into Long-term Arterial Remodeling Following BRS, DES Implantation Yael L. Maxwell June 29, 2017
News Conference News EuroPCR 2017 My Takeaways From EuroPCR 2017: Everything Perfect, Until It’s Not Shelley Wood June 02, 2017
News Features EuroPCR 2017 Seven Next-Generation Bioresorbable Scaffolds Show Promise but Face Major Hurdles Yael L. Maxwell June 01, 2017
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for May 2017 Shelley Wood June 01, 2017
News Conference News EuroPCR 2017 Scaffold Thrombosis ‘Unpredictable’ With Absorb: AIDA Analysis Michael O'Riordan May 19, 2017
News Conference News EuroPCR 2017 No Very Late Scaffold Thrombosis Risk With Absorb BVS Studies in China, Japan Michael O'Riordan May 17, 2017
News Industry News Micell Technologies Announces MiStent Achieved Primary Endpoint in All-Comers Randomized Clinical Trial Versus Xience May 16, 2017
News Conference News EuroPCR 2017 DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit Michael O'Riordan May 16, 2017